In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nabriva Therapeutics PLC

www.nabriva.com

Latest From Nabriva Therapeutics PLC

Nabriva Faces Skepticism After Years Of Preparing For Novel Antibiotic Xenleta's Launch

Lefamulin was approved in the US to treat community-acquired bacterial pneumonia, providing a needed IV and oral drug initially in the hospital setting, but new antibiotics have been a tough sell.

Infectious Diseases Approvals

Heralding Change: Product Pipeline Advances To Watch Out For In Q3

Key events that could move innovative product candidates nearer the market in the third quarter of 2019 are highlighted in a new Biomedtracker/Meddevicetracker report.

Approvals Clinical Trials

After The Peak Of 2018’s US FDA Approval Record, 2019 Looks Like A Valley

FDA’s second half 2019 user fee calendar features almost 30 novel agents, but another record-breaking tally is out of reach.

Approvals Drug Approval Standards

EU Accelerated Assessment Tracker

Accelerated assessment requests at the European Medicines Agency.

Europe Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Antibiotic Research Institute
  • Nabriva Therapeutics AG
  • 1641640
  • Nabriva Therapeutics Forschungs GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Nabriva Therapeutics PLC
  • Senior Management
  • Ted Schroeder, CEO
    Gary Sender, CFO
    Francesco Maria Lavino, Chief Commercial Officer
    Jennifer Schranz, MD, CMO
    Steven Gelone, MD, CSO & Head, Bus. Dev.
  • Contact Info
  • Nabriva Therapeutics PLC
    Phone: (43) 1 649 2000
    25-28 North Wall Quay
    Dublin, 1
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register